THE SCIENCE

Entero Therapeutics’ product portfolio is built around its three proprietary technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to break up gluten and reduce celiac disease symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist with gastrointestinal (GI) indications; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.